PSMD11 and IGSF21 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 |
immunoglobin superfamily, member 21 |
- Hedgehog 'off' state
- misspliced GSK3beta mutants stabilize beta-catenin
- Hh ligand biogenesis disease
- T41 mutants of beta-catenin aren't phosphorylated
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- Stabilization of p53
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Regulation of mRNA stability by proteins that bind AU-rich elements
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- DNA Replication Pre-Initiation
- S45 mutants of beta-catenin aren't phosphorylated
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- SCF(Skp2)-mediated degradation of p27/p21
- deletions in the AMER1 gene destabilize the destruction complex
- Autodegradation of the E3 ubiquitin ligase COP1
- AMER1 mutants destabilize the destruction complex
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- PCP/CE pathway
- Adaptive Immune System
- CDK-mediated phosphorylation and removal of Cdc6
- Hedgehog ligand biogenesis
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Separation of Sister Chromatids
- HIV Infection
- Ubiquitin-dependent degradation of Cyclin D
- APC truncation mutants have impaired AXIN binding
- Assembly of the pre-replicative complex
- Autodegradation of Cdh1 by Cdh1:APC/C
- p53-Dependent G1 DNA Damage Response
- S37 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- p53-Independent DNA Damage Response
- p53-Independent G1/S DNA damage checkpoint
- G1/S DNA Damage Checkpoints
- Vpu mediated degradation of CD4
- Synthesis of DNA
- M/G1 Transition
- Ubiquitin-dependent degradation of Cyclin D1
- TCF dependent signaling in response to WNT
- SCF-beta-TrCP mediated degradation of Emi1
- degradation of AXIN
- Signaling by Hedgehog
- Regulation of mitotic cell cycle
- Degradation of GLI1 by the proteasome
- degradation of DVL
- Cell Cycle Checkpoints
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Regulation of Apoptosis
- Degradation of GLI2 by the proteasome
- Signaling by the B Cell Receptor (BCR)
- Vif-mediated degradation of APOBEC3G
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- p53-Dependent G1/S DNA damage checkpoint
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- APC/C:Cdc20 mediated degradation of Securin
- AUF1 (hnRNP D0) destabilizes mRNA
- CDK-mediated phosphorylation and removal of Cdc6
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- truncations of AMER1 destabilize the destruction complex
- Processing-defective Hh variants abrogate ligand secretion
- Host Interactions of HIV factors
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- AXIN missense mutants destabilize the destruction complex
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Mitotic Metaphase and Anaphase
- Regulation of ornithine decarboxylase (ODC)
- Antigen processing: Ubiquitination & Proteasome degradation
- Orc1 removal from chromatin
- Mitotic Anaphase
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- Metabolism of amino acids and derivatives
- Hedgehog 'on' state
- Programmed Cell Death
- Class I MHC mediated antigen processing & presentation
- Regulation of DNA replication
- Cell Cycle, Mitotic
- beta-catenin independent WNT signaling
- Orc1 removal from chromatin
- Activation of NF-kappaB in B cells
- Asymmetric localization of PCP proteins
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Cross-presentation of soluble exogenous antigens (endosomes)
- Antigen processing-Cross presentation
- CDT1 association with the CDC6:ORC:origin complex
- ER-Phagosome pathway
|
|
|
|
|
|
PSMD6 and ZFAND5 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 |
zinc finger, AN1-type domain 5 |
- Hedgehog 'off' state
- misspliced GSK3beta mutants stabilize beta-catenin
- Hh ligand biogenesis disease
- T41 mutants of beta-catenin aren't phosphorylated
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- Stabilization of p53
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Regulation of mRNA stability by proteins that bind AU-rich elements
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- DNA Replication Pre-Initiation
- S45 mutants of beta-catenin aren't phosphorylated
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- SCF(Skp2)-mediated degradation of p27/p21
- deletions in the AMER1 gene destabilize the destruction complex
- Autodegradation of the E3 ubiquitin ligase COP1
- AMER1 mutants destabilize the destruction complex
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- PCP/CE pathway
- Adaptive Immune System
- CDK-mediated phosphorylation and removal of Cdc6
- Hedgehog ligand biogenesis
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Separation of Sister Chromatids
- HIV Infection
- Ubiquitin-dependent degradation of Cyclin D
- APC truncation mutants have impaired AXIN binding
- Assembly of the pre-replicative complex
- Autodegradation of Cdh1 by Cdh1:APC/C
- p53-Dependent G1 DNA Damage Response
- S37 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- p53-Independent DNA Damage Response
- p53-Independent G1/S DNA damage checkpoint
- G1/S DNA Damage Checkpoints
- Vpu mediated degradation of CD4
- Synthesis of DNA
- M/G1 Transition
- Ubiquitin-dependent degradation of Cyclin D1
- TCF dependent signaling in response to WNT
- SCF-beta-TrCP mediated degradation of Emi1
- degradation of AXIN
- Signaling by Hedgehog
- Regulation of mitotic cell cycle
- Degradation of GLI1 by the proteasome
- degradation of DVL
- Cell Cycle Checkpoints
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Regulation of Apoptosis
- Degradation of GLI2 by the proteasome
- Signaling by the B Cell Receptor (BCR)
- Vif-mediated degradation of APOBEC3G
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- p53-Dependent G1/S DNA damage checkpoint
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- APC/C:Cdc20 mediated degradation of Securin
- AUF1 (hnRNP D0) destabilizes mRNA
- CDK-mediated phosphorylation and removal of Cdc6
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- truncations of AMER1 destabilize the destruction complex
- Processing-defective Hh variants abrogate ligand secretion
- Host Interactions of HIV factors
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- AXIN missense mutants destabilize the destruction complex
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Mitotic Metaphase and Anaphase
- Regulation of ornithine decarboxylase (ODC)
- Antigen processing: Ubiquitination & Proteasome degradation
- Orc1 removal from chromatin
- Mitotic Anaphase
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- Metabolism of amino acids and derivatives
- Hedgehog 'on' state
- Programmed Cell Death
- Class I MHC mediated antigen processing & presentation
- Regulation of DNA replication
- Cell Cycle, Mitotic
- beta-catenin independent WNT signaling
- Orc1 removal from chromatin
- Activation of NF-kappaB in B cells
- Asymmetric localization of PCP proteins
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Cross-presentation of soluble exogenous antigens (endosomes)
- Antigen processing-Cross presentation
- CDT1 association with the CDC6:ORC:origin complex
- ER-Phagosome pathway
|
|
|
|
|
|
PSMD6 and SHFM1 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 |
split hand/foot malformation (ectrodactyly) type 1 |
- Hedgehog 'off' state
- misspliced GSK3beta mutants stabilize beta-catenin
- Hh ligand biogenesis disease
- T41 mutants of beta-catenin aren't phosphorylated
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- Stabilization of p53
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Regulation of mRNA stability by proteins that bind AU-rich elements
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- DNA Replication Pre-Initiation
- S45 mutants of beta-catenin aren't phosphorylated
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- SCF(Skp2)-mediated degradation of p27/p21
- deletions in the AMER1 gene destabilize the destruction complex
- Autodegradation of the E3 ubiquitin ligase COP1
- AMER1 mutants destabilize the destruction complex
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- PCP/CE pathway
- Adaptive Immune System
- CDK-mediated phosphorylation and removal of Cdc6
- Hedgehog ligand biogenesis
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Separation of Sister Chromatids
- HIV Infection
- Ubiquitin-dependent degradation of Cyclin D
- APC truncation mutants have impaired AXIN binding
- Assembly of the pre-replicative complex
- Autodegradation of Cdh1 by Cdh1:APC/C
- p53-Dependent G1 DNA Damage Response
- S37 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- p53-Independent DNA Damage Response
- p53-Independent G1/S DNA damage checkpoint
- G1/S DNA Damage Checkpoints
- Vpu mediated degradation of CD4
- Synthesis of DNA
- M/G1 Transition
- Ubiquitin-dependent degradation of Cyclin D1
- TCF dependent signaling in response to WNT
- SCF-beta-TrCP mediated degradation of Emi1
- degradation of AXIN
- Signaling by Hedgehog
- Regulation of mitotic cell cycle
- Degradation of GLI1 by the proteasome
- degradation of DVL
- Cell Cycle Checkpoints
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Regulation of Apoptosis
- Degradation of GLI2 by the proteasome
- Signaling by the B Cell Receptor (BCR)
- Vif-mediated degradation of APOBEC3G
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- p53-Dependent G1/S DNA damage checkpoint
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- APC/C:Cdc20 mediated degradation of Securin
- AUF1 (hnRNP D0) destabilizes mRNA
- CDK-mediated phosphorylation and removal of Cdc6
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- truncations of AMER1 destabilize the destruction complex
- Processing-defective Hh variants abrogate ligand secretion
- Host Interactions of HIV factors
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- AXIN missense mutants destabilize the destruction complex
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Mitotic Metaphase and Anaphase
- Regulation of ornithine decarboxylase (ODC)
- Antigen processing: Ubiquitination & Proteasome degradation
- Orc1 removal from chromatin
- Mitotic Anaphase
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- Metabolism of amino acids and derivatives
- Hedgehog 'on' state
- Programmed Cell Death
- Class I MHC mediated antigen processing & presentation
- Regulation of DNA replication
- Cell Cycle, Mitotic
- beta-catenin independent WNT signaling
- Orc1 removal from chromatin
- Activation of NF-kappaB in B cells
- Asymmetric localization of PCP proteins
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Cross-presentation of soluble exogenous antigens (endosomes)
- Antigen processing-Cross presentation
- CDT1 association with the CDC6:ORC:origin complex
- ER-Phagosome pathway
|
|
|
|
|
|
PSMD6 and UBQLN1 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 |
ubiquilin 1 |
- Hedgehog 'off' state
- misspliced GSK3beta mutants stabilize beta-catenin
- Hh ligand biogenesis disease
- T41 mutants of beta-catenin aren't phosphorylated
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- Stabilization of p53
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Regulation of mRNA stability by proteins that bind AU-rich elements
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- DNA Replication Pre-Initiation
- S45 mutants of beta-catenin aren't phosphorylated
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Regulation of APC/C activators between G1/S and early anaphase
- SCF(Skp2)-mediated degradation of p27/p21
- deletions in the AMER1 gene destabilize the destruction complex
- Autodegradation of the E3 ubiquitin ligase COP1
- AMER1 mutants destabilize the destruction complex
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- PCP/CE pathway
- Adaptive Immune System
- CDK-mediated phosphorylation and removal of Cdc6
- Hedgehog ligand biogenesis
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Separation of Sister Chromatids
- HIV Infection
- Ubiquitin-dependent degradation of Cyclin D
- APC truncation mutants have impaired AXIN binding
- Assembly of the pre-replicative complex
- Autodegradation of Cdh1 by Cdh1:APC/C
- p53-Dependent G1 DNA Damage Response
- S37 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- p53-Independent DNA Damage Response
- p53-Independent G1/S DNA damage checkpoint
- G1/S DNA Damage Checkpoints
- Vpu mediated degradation of CD4
- Synthesis of DNA
- M/G1 Transition
- Ubiquitin-dependent degradation of Cyclin D1
- TCF dependent signaling in response to WNT
- SCF-beta-TrCP mediated degradation of Emi1
- degradation of AXIN
- Signaling by Hedgehog
- Regulation of mitotic cell cycle
- Degradation of GLI1 by the proteasome
- degradation of DVL
- Cell Cycle Checkpoints
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Regulation of Apoptosis
- Degradation of GLI2 by the proteasome
- Signaling by the B Cell Receptor (BCR)
- Vif-mediated degradation of APOBEC3G
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- p53-Dependent G1/S DNA damage checkpoint
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- APC/C:Cdc20 mediated degradation of Securin
- AUF1 (hnRNP D0) destabilizes mRNA
- CDK-mediated phosphorylation and removal of Cdc6
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- truncations of AMER1 destabilize the destruction complex
- Processing-defective Hh variants abrogate ligand secretion
- Host Interactions of HIV factors
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- AXIN missense mutants destabilize the destruction complex
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Mitotic Metaphase and Anaphase
- Regulation of ornithine decarboxylase (ODC)
- Antigen processing: Ubiquitination & Proteasome degradation
- Orc1 removal from chromatin
- Mitotic Anaphase
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- Metabolism of amino acids and derivatives
- Hedgehog 'on' state
- Programmed Cell Death
- Class I MHC mediated antigen processing & presentation
- Regulation of DNA replication
- Cell Cycle, Mitotic
- beta-catenin independent WNT signaling
- Orc1 removal from chromatin
- Activation of NF-kappaB in B cells
- Asymmetric localization of PCP proteins
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Cross-presentation of soluble exogenous antigens (endosomes)
- Antigen processing-Cross presentation
- CDT1 association with the CDC6:ORC:origin complex
- ER-Phagosome pathway
|
|
|
|
|
|
JAK2 and IRS1 |
Janus kinase 2 |
insulin receptor substrate 1 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- SOS-mediated signalling
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- IRS activation
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
|
JAK2 and INSR |
Janus kinase 2 |
insulin receptor |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Insulin receptor signalling cascade
- IRS activation
- Signal attenuation
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- SHC activation
- Signaling by Insulin receptor
|
|
- Insulin Regular
- Insulin Lispro
- Insulin Glargine
- Insulin, porcine
- Mecasermin
- Insulin Aspart
- Insulin Detemir
- Insulin Glulisine
- Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- Insulin, isophane
|
|
|
JAK2 and CTLA4 |
Janus kinase 2 |
cytotoxic T-lymphocyte-associated protein 4 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Costimulation by the CD28 family
- CTLA4 inhibitory signaling
- Adaptive Immune System
|
|
|
|
|
JAK2 and ERBB3 |
Janus kinase 2 |
erb-b2 receptor tyrosine kinase 3 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|
|
JAK1 and TYK2 |
Janus kinase 1 |
tyrosine kinase 2 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by GPCR
- Signaling by FGFR in disease
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- DAP12 signaling
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- TRIF-mediated TLR3/TLR4 signaling
- SHC-related events triggered by IGF1R
- ERK1 activation
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- ERK1 activation
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Downstream signal transduction
- Signalling to RAS
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- ERK activation
- IRS-mediated signalling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Interleukin-6 signaling
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- ERK activation
- Downstream signaling of activated FGFR
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Interferon alpha/beta signaling
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Interferon Signaling
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- MyD88-independent cascade
- ERK2 activation
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- SHC1 events in EGFR signaling
- Toll Like Receptor 10 (TLR10) Cascade
- FRS2-mediated cascade
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK2 activation
|
|
|
|
|
JAK1 and IRS1 |
Janus kinase 1 |
insulin receptor substrate 1 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- SOS-mediated signalling
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- IRS activation
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
|
JAK1 and SYK |
Janus kinase 1 |
spleen tyrosine kinase |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by the B Cell Receptor (BCR)
- FCERI mediated MAPK activation
- Platelet Aggregation (Plug Formation)
- DAP12 signaling
- Regulation of signaling by CBL
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- DAP12 interactions
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
|
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic Acid
|
|
|
JAK1 and IL2RB |
Janus kinase 1 |
interleukin 2 receptor, beta |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by GPCR
- G-protein beta:gamma signalling
- Cytokine Signaling in Immune system
- Signaling by Interleukins
- GPCR downstream signaling
- Interleukin receptor SHC signaling
- G beta:gamma signalling through PI3Kgamma
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
|
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
|
|
|
JAK1 and INSR |
Janus kinase 1 |
insulin receptor |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Insulin receptor signalling cascade
- IRS activation
- Signal attenuation
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- SHC activation
- Signaling by Insulin receptor
|
|
- Insulin Regular
- Insulin Lispro
- Insulin Glargine
- Insulin, porcine
- Mecasermin
- Insulin Aspart
- Insulin Detemir
- Insulin Glulisine
- Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- Insulin, isophane
|
|
|
JAK1 and IL7R |
Janus kinase 1 |
interleukin 7 receptor |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Signaling by Interleukins
- Interleukin-7 signaling
- Cytokine Signaling in Immune system
|
|
|
|
|
JAK1 and PTPN2 |
Janus kinase 1 |
protein tyrosine phosphatase, non-receptor type 2 |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
|
|
|
|
|
PPP2CA and CDK2 |
protein phosphatase 2, catalytic subunit, alpha isozyme |
cyclin-dependent kinase 2 |
- Signaling by GPCR
- Integration of energy metabolism
- Signaling by FGFR in disease
- Mitotic Prophase
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- ERKs are inactivated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Glycolysis
- Signaling by Wnt
- Glucose metabolism
- Toll Like Receptor TLR1:TLR2 Cascade
- Degradation of beta-catenin by the destruction complex
- Toll Like Receptor 5 (TLR5) Cascade
- RNF mutants show enhanced WNT signaling and proliferation
- Myoclonic epilepsy of Lafora
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- G1/S Transition
- Glycogen storage diseases
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Beta-catenin phosphorylation cascade
- Initiation of Nuclear Envelope Reformation
- Mitotic G1-G1/S phases
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Spry regulation of FGF signaling
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- Toll Like Receptor 2 (TLR2) Cascade
- Platelet homeostasis
- deletions in the AMER1 gene destabilize the destruction complex
- Platelet sensitization by LDL
- AMER1 mutants destabilize the destruction complex
- Resolution of Sister Chromatid Cohesion
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Metabolism of carbohydrates
- Mitotic G2-G2/M phases
- Mitotic Metaphase and Anaphase
- Adaptive Immune System
- PP2A-mediated dephosphorylation of key metabolic factors
- MASTL Facilitates Mitotic Progression
- Mitotic Prometaphase
- Costimulation by the CD28 family
- Separation of Sister Chromatids
- APC truncation mutants have impaired AXIN binding
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- G2/M Transition
- Mitotic Anaphase
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Activated TLR4 signalling
- S37 mutants of beta-catenin aren't phosphorylated
- MyD88 cascade initiated on plasma membrane
- Cyclin A/B1 associated events during G2/M transition
- XAV939 inhibits tankyrase, stabilizing AXIN
- DARPP-32 events
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Nuclear Envelope Reassembly
- Innate Immune System
- Nonsense-Mediated Decay (NMD)
- E2F mediated regulation of DNA replication
- ERKs are inactivated
- Signalling by NGF
- MAP kinase activation in TLR cascade
- CTLA4 inhibitory signaling
- G1 Phase
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Cell Cycle, Mitotic
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Cyclin D associated events in G1
- Toll Like Receptor 10 (TLR10) Cascade
- TCF dependent signaling in response to WNT
- ERK/MAPK targets
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by WNT in cancer
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Nuclear Events (kinase and transcription factor activation)
|
- CDK-mediated phosphorylation and removal of Cdc6
- G2/M Checkpoints
- Activation of the pre-replicative complex
- Cellular Senescence
- Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
- G2/M Transition
- p53-Dependent G1/S DNA damage checkpoint
- Activation of the pre-replicative complex
- Orc1 removal from chromatin
- Cyclin E associated events during G1/S transition
- CDK-mediated phosphorylation and removal of Cdc6
- p53-Dependent G1 DNA Damage Response
- Cyclin A/B1 associated events during G2/M transition
- G2 Phase
- Activation of ATR in response to replication stress
- G1/S Transition
- Removal of licensing factors from origins
- Mitotic G1-G1/S phases
- Switching of origins to a post-replicative state
- G1/S DNA Damage Checkpoints
- Meiotic recombination
- DNA Damage/Telomere Stress Induced Senescence
- Synthesis of DNA
- DNA Replication Pre-Initiation
- M/G1 Transition
- Regulation of DNA replication
- Senescence-Associated Secretory Phenotype (SASP)
- G0 and Early G1
- S Phase
- Regulation of APC/C activators between G1/S and early anaphase
- Factors involved in megakaryocyte development and platelet production
- Cell Cycle, Mitotic
- APC/C-mediated degradation of cell cycle proteins
- SCF(Skp2)-mediated degradation of p27/p21
- Orc1 removal from chromatin
- Regulation of mitotic cell cycle
- Cell Cycle Checkpoints
- SCF(Skp2)-mediated degradation of p27/p21
- Cyclin A:Cdk2-associated events at S phase entry
- Mitotic G2-G2/M phases
|
|
- Double Oxidized Cysteine
- 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
- Staurosporine
- Indirubin-3\'-Monoxime
- 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
- Olomoucine
- 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
- 2-Amino-6-Chloropyrazine
- 6-O-Cyclohexylmethyl Guanine
- N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
- 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
- N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
- Purvalanol
- [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
- 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone
- 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine
- Hymenialdisine
- (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
- 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
- 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
- 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
- 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
- SU9516
- 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
- Flavopiridol
- (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One
- 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
- 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
- Lysine Nz-Carboxylic Acid
- [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
- Alsterpaullone
- N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide
- N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
- 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
- 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
- 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
- PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
- OLOMOUCINE II
- TRIAZOLOPYRIMIDINE
- Bosutinib
- 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
- (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
- N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE
- 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
- 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
- (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
- 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
- (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
- 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
- O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE
- (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE
- 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
- N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
- 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
- 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE
- 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
- N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
- (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
- 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
- (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE
- (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
- (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
- 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE
- 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
- 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
- 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
- N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE
- (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
- 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
- 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
- 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
- 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
- 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
- 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
- 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
- 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
- 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL
- (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
- (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
- (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
- (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
- N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
- 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
- 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
- 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL
- N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
- 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
- N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
- (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
- N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
- 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
- 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
- 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
- 5-hydroxynaphthalene-1-sulfonamide
- N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
- 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
- N-phenyl-1H-pyrazole-3-carboxamide
- 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
- (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
- {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
- 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
- 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
- 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
- 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
- 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
- HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
- 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE
- 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE
- 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
- 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
- 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
- (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
- 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
- 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
- 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
- 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
- (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
- 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
- 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
- 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
- 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
- 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
- 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
- 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
- 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
- N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
- 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
- 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
- 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
- N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE
- 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
- N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
|
|
|
PPP2CA and MYH9 |
protein phosphatase 2, catalytic subunit, alpha isozyme |
myosin, heavy chain 9, non-muscle |
- Signaling by GPCR
- Integration of energy metabolism
- Signaling by FGFR in disease
- Mitotic Prophase
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- ERKs are inactivated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Glycolysis
- Signaling by Wnt
- Glucose metabolism
- Toll Like Receptor TLR1:TLR2 Cascade
- Degradation of beta-catenin by the destruction complex
- Toll Like Receptor 5 (TLR5) Cascade
- RNF mutants show enhanced WNT signaling and proliferation
- Myoclonic epilepsy of Lafora
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- G1/S Transition
- Glycogen storage diseases
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Beta-catenin phosphorylation cascade
- Initiation of Nuclear Envelope Reformation
- Mitotic G1-G1/S phases
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Spry regulation of FGF signaling
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- Toll Like Receptor 2 (TLR2) Cascade
- Platelet homeostasis
- deletions in the AMER1 gene destabilize the destruction complex
- Platelet sensitization by LDL
- AMER1 mutants destabilize the destruction complex
- Resolution of Sister Chromatid Cohesion
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Metabolism of carbohydrates
- Mitotic G2-G2/M phases
- Mitotic Metaphase and Anaphase
- Adaptive Immune System
- PP2A-mediated dephosphorylation of key metabolic factors
- MASTL Facilitates Mitotic Progression
- Mitotic Prometaphase
- Costimulation by the CD28 family
- Separation of Sister Chromatids
- APC truncation mutants have impaired AXIN binding
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- G2/M Transition
- Mitotic Anaphase
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Activated TLR4 signalling
- S37 mutants of beta-catenin aren't phosphorylated
- MyD88 cascade initiated on plasma membrane
- Cyclin A/B1 associated events during G2/M transition
- XAV939 inhibits tankyrase, stabilizing AXIN
- DARPP-32 events
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Nuclear Envelope Reassembly
- Innate Immune System
- Nonsense-Mediated Decay (NMD)
- E2F mediated regulation of DNA replication
- ERKs are inactivated
- Signalling by NGF
- MAP kinase activation in TLR cascade
- CTLA4 inhibitory signaling
- G1 Phase
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Cell Cycle, Mitotic
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Cyclin D associated events in G1
- Toll Like Receptor 10 (TLR10) Cascade
- TCF dependent signaling in response to WNT
- ERK/MAPK targets
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by WNT in cancer
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Nuclear Events (kinase and transcription factor activation)
|
- EPHA-mediated growth cone collapse
- Axon guidance
- Semaphorin interactions
- EPH-Ephrin signaling
- Sema4D in semaphorin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
|
|
|
|
|
PPP2CA and NXN |
protein phosphatase 2, catalytic subunit, alpha isozyme |
nucleoredoxin |
- Signaling by GPCR
- Integration of energy metabolism
- Signaling by FGFR in disease
- Mitotic Prophase
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- ERKs are inactivated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Glycolysis
- Signaling by Wnt
- Glucose metabolism
- Toll Like Receptor TLR1:TLR2 Cascade
- Degradation of beta-catenin by the destruction complex
- Toll Like Receptor 5 (TLR5) Cascade
- RNF mutants show enhanced WNT signaling and proliferation
- Myoclonic epilepsy of Lafora
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- G1/S Transition
- Glycogen storage diseases
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Beta-catenin phosphorylation cascade
- Initiation of Nuclear Envelope Reformation
- Mitotic G1-G1/S phases
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Spry regulation of FGF signaling
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
- Toll Like Receptor 2 (TLR2) Cascade
- Platelet homeostasis
- deletions in the AMER1 gene destabilize the destruction complex
- Platelet sensitization by LDL
- AMER1 mutants destabilize the destruction complex
- Resolution of Sister Chromatid Cohesion
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Metabolism of carbohydrates
- Mitotic G2-G2/M phases
- Mitotic Metaphase and Anaphase
- Adaptive Immune System
- PP2A-mediated dephosphorylation of key metabolic factors
- MASTL Facilitates Mitotic Progression
- Mitotic Prometaphase
- Costimulation by the CD28 family
- Separation of Sister Chromatids
- APC truncation mutants have impaired AXIN binding
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- G2/M Transition
- Mitotic Anaphase
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Activated TLR4 signalling
- S37 mutants of beta-catenin aren't phosphorylated
- MyD88 cascade initiated on plasma membrane
- Cyclin A/B1 associated events during G2/M transition
- XAV939 inhibits tankyrase, stabilizing AXIN
- DARPP-32 events
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Nuclear Envelope Reassembly
- Innate Immune System
- Nonsense-Mediated Decay (NMD)
- E2F mediated regulation of DNA replication
- ERKs are inactivated
- Signalling by NGF
- MAP kinase activation in TLR cascade
- CTLA4 inhibitory signaling
- G1 Phase
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Cell Cycle, Mitotic
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Cyclin D associated events in G1
- Toll Like Receptor 10 (TLR10) Cascade
- TCF dependent signaling in response to WNT
- ERK/MAPK targets
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by WNT in cancer
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Nuclear Events (kinase and transcription factor activation)
|
|
|
|
|
|
CREB1 and PDX1 |
cAMP responsive element binding protein 1 |
pancreatic and duodenal homeobox 1 |
- Signaling by the B Cell Receptor (BCR)
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- NOTCH2 intracellular domain regulates transcription
- Signaling by SCF-KIT
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Signaling by NOTCH2
- PI3K/AKT activation
- Toll Like Receptor 5 (TLR5) Cascade
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- PKA-mediated phosphorylation of CREB
- GAB1 signalosome
- Signaling by NOTCH
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- CREB phosphorylation through the activation of Adenylate Cyclase
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- PKA-mediated phosphorylation of CREB
- Signaling by EGFR
- CREB phosphorylation through the activation of CaMKK
- AKT phosphorylates targets in the nucleus
- Calmodulin induced events
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Downstream signal transduction
- CREB phosphorylation through the activation of CaMKII
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Transmission across Chemical Synapses
- Adaptive Immune System
- Organelle biogenesis and maintenance
- CREB phosphorylation
- Axon guidance
- PIP3 activates AKT signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- CREB phosphorylation
- DAG and IP3 signaling
- Toll Like Receptor TLR6:TLR2 Cascade
- CaM pathway
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- PI3K events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- Downstream signaling of activated FGFR
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- Post NMDA receptor activation events
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- MAP kinase activation in TLR cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- G-protein mediated events
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- PLC-gamma1 signalling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in beta cells
|
- Adenosine monophosphate
- Naloxone
|
|
|
|
CREB1 and HNF1B |
cAMP responsive element binding protein 1 |
HNF1 homeobox B |
- Signaling by the B Cell Receptor (BCR)
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- NOTCH2 intracellular domain regulates transcription
- Signaling by SCF-KIT
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Signaling by NOTCH2
- PI3K/AKT activation
- Toll Like Receptor 5 (TLR5) Cascade
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- PKA-mediated phosphorylation of CREB
- GAB1 signalosome
- Signaling by NOTCH
- TRIF-mediated TLR3/TLR4 signaling
- Opioid Signalling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- CREB phosphorylation through the activation of Adenylate Cyclase
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- PKA-mediated phosphorylation of CREB
- Signaling by EGFR
- CREB phosphorylation through the activation of CaMKK
- AKT phosphorylates targets in the nucleus
- Calmodulin induced events
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Downstream signal transduction
- CREB phosphorylation through the activation of CaMKII
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Transmission across Chemical Synapses
- Adaptive Immune System
- Organelle biogenesis and maintenance
- CREB phosphorylation
- Axon guidance
- PIP3 activates AKT signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- CREB phosphorylation
- DAG and IP3 signaling
- Toll Like Receptor TLR6:TLR2 Cascade
- CaM pathway
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- PI3K events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- Downstream signaling of activated FGFR
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- Post NMDA receptor activation events
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- MAP kinase activation in TLR cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- G-protein mediated events
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- Signaling by FGFR
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- PLC-gamma1 signalling
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
- Adenosine monophosphate
- Naloxone
|
|
|
|